✦ LIBER ✦

494 A phase I trial of SCH900776, a selective inhibitor of checkpoint kinase CHK-1, in combination with Gemcitabine in advanced solid tumors

✍ Scribed by A. Daud; C. Soon; G. Springett; D. Mendelson; P. Munster; J. Goldman; J. Strosberg; G. Kato; J. Horowitz; L. Rosen

Book ID: 119603177
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 48 KB
Volume: 8
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(10)72201-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I dose-escalation study of AZD7762

Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors

✍ Sausville, Edward; LoRusso, Patricia; Carducci, Michael; Carter, Judith; Quinn, 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 560 KB

A phase I trial of gemcitabine in combin

A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors

✍ William Schelman; Sherry Morgan-Meadows; Howard Bailey; Kyle Holen; James P. Tho 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 325 KB

395 POSTER Phase I study of XL844, a nov

395 POSTER Phase I study of XL844, a novel Chk1 and Chk2 kinase inhibitor, in combination with gemcitabine in patients with advanced malignancies

✍ A. Tse; S. Yazji; A. Naing; D. Matthews; G. Schwartz; K. Lawhorn; R. Kurzrock 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 57 KB

Phase I clinical trial of bortezomib in

Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors

✍ David P. Ryan; Leonard J. Appleman; Thomas Lynch; Jeffrey G. Supko; Panagiotis F 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB 👁 2 views

## Abstract ## BACKGROUND. Bortezomib is the first proteasome inhibitor to show preliminary evidence of activity against solid tumors. Findings from preclinical studies prompted a Phase I trial to determine the maximum tolerated dose (MTD) and dose‐limiting toxicities (DLTs) of bortezomib in combi

A Phase I study of pazopanib in combinat

A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors

✍ Ruth Plummer, Ayman Madi, Melinda Jeffels… 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 266 KB

Phase 1 study of MLN8054, a selective in

Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors

✍ E. Claire Dees; Jeffrey R. Infante; Roger B. Cohen; Bert H. O’Neil; Suzanne Jone 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 328 KB